SOURCE: STRATEGIC BIOLOGICAL SYSTEMS (SBS) DIVISION – PR UNIT
STATUS: CLEARED FOR PUBLIC DISTRIBUTION
LAST RELEASE CYCLE: [REDACTED]

This directory contains press materials, sanitized public announcements, and controlled messaging surrounding the Chimera-class platform. All entries have been reviewed and authorized for external consumption under Halcyon’s Disclosure Protocols for Emerging Biotech (DPEB/17).

Media materials are intended for:

• Investor briefings
• Client-facing capability showcases
• Civilian reassurance strategies
• Strategic positioning during leak events

Discrepancies between internal documentation and public claims are not considered contradictions under Halcyon Legal Doctrine 4B (“Contextual Framing in Corporate Disclosure”).

Included Materials

• Product Launch Announcements
• Strategic Capability Highlights
• Public-Relations Approved Messaging
• Export Compliance Language

NOTICE:
Use of gendered or empathetic terminology in these documents is intentional and non-binding.
Statements do not reflect internal policy, legal status, or operational constraints.